Everolimus and exemestane in hormone receptor positive advanced breast cancer: A comprehensive cancer center's experience

Bull Cancer. 2022 Jun;109(6):723-725. doi: 10.1016/j.bulcan.2022.02.015. Epub 2022 May 18.

Authors

Inês Moreira¹, Ana Afonso², Miguel Abreu², Susana Sousa², Marta Ferreira²

Affiliations

¹ Oncology Department, Portuguese Institute of Oncology Francisco Gentil, Rua Dr. António Bernardino de Almeida 865, 4200-072 Porto, Portugal. Electronic address: ines.almeida.moreira@ipoporto.min-saude.pt.
² Oncology Department, Portuguese Institute of Oncology Francisco Gentil, Rua Dr. António Bernardino de Almeida 865, 4200-072 Porto, Portugal.

PMID: 35597619
DOI: 10.1016/j.bulcan.2022.02.015

No abstract available

Publication types

Letter

MeSH terms

Androstadienes / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms* / drug therapy
Everolimus* / therapeutic use
Female
Humans
Receptor, ErbB-2

Substances

Androstadienes
Everolimus
Receptor, ErbB-2
exemestane